Personal Home Page

http://medicalcenter.osu.edu/patientcare/findadoctor/directory/index.cfm?DocID=063610&SIDS=

Articles in Scholarly Journals [Incomplete List]

1. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis
   Clinical Immunology, vol. 128, no. 3, pp. 382–391, 2008
2. Monoclonal Antibody Therapies and Neurologic Disorders
   Archives of Neurology, vol. 65, no. 9, pp. 1162–1165, 2008
3. Autologous HSCT for advanced MS: Is the glass half-empty or really half-full?
   Brain, vol. 131, no. 2, pp. e89–e89, 2008
4. PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis
   PPAR Research, vol. 2008, Article ID 546753, 6 pages, 2008
5. PPAR-γ: Therapeutic Potential for Multiple Sclerosis
   PPAR Research, vol. 2008, Article ID 627463, 9 pages, 2008
6. Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients
   PLoS ONE, vol. 3, no. 4, p. e2028, 2008
7. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies
   Current Opinion in Neurology, vol. 21, no. Suppl 1, pp. S9–S18, 2008
8. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
   Neurology, vol. 71, no. 2, pp. 136–144, 2008
9. Peroxisome proliferator-activated receptor-α agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis
   Journal of Neurochemistry, vol. 103, no. 5, pp. 1801–1810, 2007
10. Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection?
    Journal of Neuroimmunology, vol. 183, no. 1-2, pp. 189–199, 2007
11. Genetic analysis of the exon 1 position 49 CD152 dimorphism in multiple sclerosis
    Journal of Neuroimmunology, vol. 191, no. 1-2, pp. 45–50, 2007
12. Humoral Immune Responses After Rabies Infection
    Archives of Neurology, vol. 64, no. 9, pp. 1355–1356, 2007
13. Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS?
    Journal of Neuroimmunology, vol. 186, no. 1-2, pp. 164–176, 2007
14. High Incidence of Post-Lumbar Puncture Headaches in Patients With Multiple Sclerosis Treated With Natalizumab: Role of Intrathecal Leukocytes
    Archives of Neurology, vol. 64, no. 7, pp. 1055–1056, 2007
15. CD28:B7 interaction is necessary for the protective effect of T cell vaccination in EAE
    European Journal of Immunology, vol. 37, no. 7, pp. 2032–2042, 2007
16. Immune surveillance in multiple sclerosis patients treated with natalizumab
    Annals of Neurology, vol. 59, no. 5, pp. 743–747, 2006
17. Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis
    Archives of Neurology, vol. 63, no. 4, pp. 614–619, 2006
18. Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis
    Archives of Neurology, vol. 63, no. 10, pp. 1383–1387, 2006
19. Peroxisome proliferator-activated receptor-a and retinoid X receptor agonists inhibit inflammatory responses of astrocytes
    Journal of Neuroimmunology, vol. 176, no. 1-2, pp. 95–105, 2006
20. CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate
    Journal of Neuroimmunology, vol. 178, no. 1-2, pp. 117–129, 2006
21. Peroxisome proliferator-activated receptor agonist regulation of glial activation: Relevance to CNS inflammatory disorders
    Neurochemistry International, vol. 49, no. 2, pp. 183–189, 2006
22. Epstein-Barr Virus and Multiple Sclerosis
    Archives of Neurology, vol. 63, no. 6, pp. 810–811, 2006
23. Multiple Sclerosis -- The Plaque and Its Pathogenesis
    New England Journal of Medicine, vol. 354, no. 9, pp. 942–955, 2006
24. Phenotypic characterization of autoreactive T cells in multiple sclerosis
    Journal of Neuroimmunology, vol. 178, no. 1-2, pp. 100–110, 2006
25. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis
    Journal of Neuroimmunology, vol. 180, no. 1-2, pp. 159–171, 2006
26. Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity
    Journal of Neuroimmunology, vol. 172, no. 1-2, pp. 94–103, 2006
27. PTX cruiser: driving autoimmunity via TLR4
    Trends in Immunology, vol. 26, no. 6, pp. 289–291, 2005
28. Glatiramer Acetate Therapy: The Plot Thickens
    Archives of Neurology, vol. 62, no. 6, pp. 858–859, 2005
29. Effect of Rituximab on the Peripheral Blood and Cerebrospinal Fluid B Cells in Patients With Primary Progressive Multiple Sclerosis
    Archives of Neurology, vol. 62, no. 2, pp. 258–264, 2005
30. Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients
    Journal of Neuroimmunology, vol. 158, no. 1-2, pp. 170–181, 2005
31. Characterizing the Mechanisms of Progression in Multiple Sclerosis: Evidence and New Hypotheses for Future Directions
    Archives of Neurology, vol. 62, no. 9, pp. 1345–1356, 2005
32. Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis: A Consensus Statement
    Archives of Neurology, vol. 62, no. 6, pp. 865–870, 2005
33. Therapeutic Potential of Small Interfering RNA for Central Nervous System Diseases
    Archives of Neurology, vol. 62, no. 12, pp. 1810–1813, 2005
34. Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations
    Archives of Neurology, vol. 62, no. 10, pp. 1519–1530, 2005
35. Agonists for the peroxisome proliferator-activated receptor-a and the retinoid X receptor inhibit inflammatory responses of microglia
    Journal of Neuroscience Research, vol. 81, no. 3, pp. 403–411, 2005
36. Fatigue in Multiple Sclerosis: Is the Picture Getting Simpler or More Complex?
    Archives of Neurology, vol. 61, no. 2, pp. 176–177, 2004
37. Viral Pathogens in Multiple Sclerosis: An Intriguing (Hi)story
    Archives of Neurology, vol. 61, no. 10, pp. 1500–1502, 2004
38. Silencing T-bet Defines a Critical Role in the Differentiation of Autoreactive T Lymphocytes
    Immunity, vol. 21, no. 5, pp. 719–731, 2004
39. Ligands for the peroxisome proliferator-activated receptor-? and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis
    Journal of Neuroimmunology, vol. 148, no. 1-2, pp. 116–126, 2004
40. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay
    Blood, vol. 103, no. 11, pp. 4222–4231, 2004
41. Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management
    Multiple Sclerosis, vol. 10, no. 3, pp. 302–307, 2004
42. Mycophenolate Mofetil in Multiple Sclerosis
    Clinical Neuropharmacology, vol. 27, no. 2, pp. 80–83, 2004
43. Decreased expression of Src homology 2 domain-containing protein tyrosine phosphatase 1 reduces T cell activation threshold but not the severity of experimental autoimmune myasthenia gravis
    Journal of Neuroimmunology, vol. 138, no. 1-2, pp. 76–82, 2003
44. Levetiracetam for Phasic Spasticity in Multiple Sclerosis
    Archives of Neurology, vol. 60, no. 12, pp. 1772–1774, 2003
45. Retinoic acid promotes the development of Th2-like human myelin basic protein-reactive T cells
    Cellular Immunology, vol. 215, no. 1, pp. 54–60, 2002
46. Disease-Modifying Therapy in Multiple Sclerosis: Strategies For Optimizing Management
    The Neurologist, vol. 8, no. 4, pp. 227–236, 2002
47. Targeting T cell costimulation in autoimmune disease
    Expert Opinion on Therapeutic Targets, vol. 6, no. 3, pp. 275–289, 2002
48. Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis
    Journal of Clinical Investigation, vol. 109, no. 5, pp. 641–649, 2002
49. Quantitative oculographic characterisation of internuclear ophthalmoparesis in multiple sclerosis: the versional dysconjugacy index Z score
    Journal of Neurology, Neurosurgery & Psychiatry, vol. 73, no. 1, pp. 51–55, 2002
50. Ocular contrapulsion in multiple sclerosis: clinical features and pathophysiological mechanisms
    Journal of Neurology, Neurosurgery & Psychiatry, vol. 70, no. 5, pp. 688–692, 2001
51. Journal of Clinical Immunology, vol. 21, no. 2, pp. 61–73, 2001
52. Multiple Sclerosis and Magnetic Resonance Imaging: Advancement in Linking the Pictures With the Progression
    Archives of Neurology, vol. 58, no. 1, pp. 35–36, 2001
53. Role of nerve growth factor in experimental autoimmune encephalomyelitis
    European Journal of Immunology, vol. 31, no. 2, pp. 625–633, 2001
54. To Treat, or Not to Treat: The Therapeutic Dilemma of Idiopathic Monosymptomatic Demyelinating Syndromes
    Archives of Neurology, vol. 57, no. 7, pp. 930–932, 2000
55. The role of costimulation in autoimmune demyelination
    Journal of Neuroimmunology, vol. 107, no. 2, pp. 205–215, 2000
56. Developmentally regulated gene expression of Th2 cytokines in the brain
    Brain Research, vol. 870, no. 1-2, pp. 27–35, 2000
57. Retrovirus mediated gene transfer of the self antigen MBP into the bone marrow of mice alters resistance to experimental autoimmune encephalomyelitis
    Journal of Neuroimmunology, vol. 103, no. 1, pp. 51–62, 2000
58. The role of CTLA-4 in tolerance induction and Ttigen administration cell differentiation in experimental autoimmune encephalomyelitis: i.v. antigen administration
    International Immunology, vol. 11, no. 12, pp. 1889–1896, 1999
59. T cells are the main cell type expressing B7-1 and B7-2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis
    European Journal of Immunology, vol. 29, no. 10, pp. 3140–3147, 1999
60. The role of CTLA-4 in tolerance induction and T cell differentiation in experimental autoimmune encephalomyelitis: i.p. antigen administration
    International Immunology, vol. 11, no. 12, pp. 1881–1888, 1999
61. Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3).
    Journal of Clinical Investigation, vol. 101, no. 8, pp. 1797–1804, 1998
62. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells.
    Journal of Clinical Investigation, vol. 101, no. 4, pp. 725–730, 1998
63. Bystander suppression in experimental autoimmune encephalomyelitis: where and how does it occur?
    Research in Immunology, vol. 149, no. 9, pp. 820–827, 1998
64. Longitudinal study of myelin basic protein-specific T-cell receptors during the course of multiple sclerosis
    Journal of Neuroimmunology, vol. 78, no. 1-2, pp. 162–171, 1997
65. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease
    Journal of Neuroimmunology, vol. 79, no. 1, pp. 54–61, 1997
66. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease
    Immunology Today, vol. 17, no. 5, pp. 225–231, 1996
67. Intravenous antigen adrmnistration as a therapy for autoimmune demyelinating disease
    Annals of Neurology, vol. 39, no. 1, pp. 46–56, 1996
68. Opposing effects of CTLA4-Ig and Anti-CD80 (B7-1) plus Anti-CD86 (B7-2) on experimental allergic encephalomyelitis
    Journal of Neuroimmunology, vol. 65, no. 1, pp. 31–39, 1996
69. B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis
    Immunologic Research, vol. 14, no. 3, pp. 189–199, 1995
70. IVth Congress of the International Society of Neuroimmunology Amsterdam, the Netherlands, 23–27 October 1994
    Journal of Neuroimmunology, vol. 58, no. 1, pp. 117–120, 1995
71. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.
    Journal of Clinical Investigation, vol. 96, no. 5, pp. 2195–2203, 1995
72. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease
    Journal of Experimental Medicine, vol. 180, no. 5, pp. 1961–1966, 1994
73. Molecular Cloning and Functional Expression of 5-HT1E-Like Rat and Human 5-Hydroxytryptamine Receptor Genes
    Proceedings of the National Academy of Sciences, vol. 90, no. 6, pp. 2184–2188, 1993
74. Two Members of a Distinct Subfamily of 5-Hydroxytryptamine Receptors Differentially Expressed in Rat Brain
    Proceedings of the National Academy of Sciences, vol. 90, no. 8, pp. 3452–3456, 1993
75. Cytokine-regulated adhesion between encephalitogenic T lymphocytes and cerebrovascular endothelial cells
    Journal of Neuroimmunology, vol. 43, no. 1-2, pp. 23–30, 1993
76. Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-ß2
    Journal of Neuroimmunology, vol. 46, no. 1-2, pp. 175–183, 1993
77. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms
    Neuron, vol. 11, no. 3, pp. 449–458, 1993
78. Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation
    Journal of Neuroimmunology, vol. 37, no. 1-2, pp. 75–84, 1992